Sabina Abidi1, Irfan Mian2, Iliana Garcia-Ortega3, Tania Lecomte4, Thomas Raedler5, Kevin Jackson6, Kim Jackson6, Tamara Pringsheim7, Donald Addington7. 1. 1 Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia. 2. 2 Department of Psychiatry, University of Toronto, Toronto, Ontario. 3. 3 Department of Psychiatry, University of Calgary, Calgary, Alberta. 4. 4 Department of Psychology, University of Montreal, Montreal, Quebec. 5. 5 Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta. 6. 6 Schizophrenia Society of Alberta, Lethbridge, Alberta. 7. 7 Mathison Centre for Mental Health Research and Education, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta.
Abstract
OBJECTIVE: Schizophrenia spectrum and other psychotic disorders often have their onset in adolescence. The sequelae of these illnesses can negatively alter the trajectory of emotional, cognitive, and social development in children and youth if left untreated. Early and appropriate interventions can improve outcomes. This article aims to identify best practices in the pharmacotherapy management of children and youth with schizophrenia spectrum disorders. METHODS: A systematic search was conducted for published guidelines for schizophrenia and schizophrenia spectrum disorders in children and youth (under age 18 years). Recommendations were drawn from the National Institute for Health and Care Excellence guidelines on psychosis and schizophrenia in children and youth (2013 and 2015 updates). Current guidelines were adopted using the ADAPTE process, which includes consensus ratings by a panel of experts. RESULTS: Recommendations identified covered a range of issues in the pharmacotherapy management of children and youth with schizophrenia spectrum disorders. Further work in this area is warranted as we continue to further understand their presentation in the developing brain. CONCLUSIONS: Canadian guidelines for the pharmacotherapy management of children and youth with schizophrenia spectrum disorders are essential to assist clinicians in treating this vulnerable population. Ongoing work in this area is recommended.
OBJECTIVE:Schizophrenia spectrum and other psychotic disorders often have their onset in adolescence. The sequelae of these illnesses can negatively alter the trajectory of emotional, cognitive, and social development in children and youth if left untreated. Early and appropriate interventions can improve outcomes. This article aims to identify best practices in the pharmacotherapy management of children and youth with schizophrenia spectrum disorders. METHODS: A systematic search was conducted for published guidelines for schizophrenia and schizophrenia spectrum disorders in children and youth (under age 18 years). Recommendations were drawn from the National Institute for Health and Care Excellence guidelines on psychosis and schizophrenia in children and youth (2013 and 2015 updates). Current guidelines were adopted using the ADAPTE process, which includes consensus ratings by a panel of experts. RESULTS: Recommendations identified covered a range of issues in the pharmacotherapy management of children and youth with schizophrenia spectrum disorders. Further work in this area is warranted as we continue to further understand their presentation in the developing brain. CONCLUSIONS: Canadian guidelines for the pharmacotherapy management of children and youth with schizophrenia spectrum disorders are essential to assist clinicians in treating this vulnerable population. Ongoing work in this area is recommended.
Entities:
Keywords:
adolescent-onset schizophrenia; children and youth; clinical practice guidelines; early-onset schizophrenia; pharmacotherapy; schizophrenia and psychotic spectrum disorders; treatment guidelines
Authors: William A Vega; Sergio Aguilar-Gaxiola; Laura Andrade; Rob Bijl; Guilherme Borges; Jorge J Caraveo-Anduaga; David J DeWit; Steven G Heeringa; Ronald C Kessler; Bo Kolody; Kathleen R Merikangas; Beth E Molnar; Ellen E Walters; Lynn A Warner; Hans-Ulrich Wittchen Journal: Drug Alcohol Depend Date: 2002-12-01 Impact factor: 4.492
Authors: Melissa C Brouwers; Michelle E Kho; George P Browman; Jako S Burgers; Francoise Cluzeau; Gene Feder; Béatrice Fervers; Ian D Graham; Jeremy Grimshaw; Steven E Hanna; Peter Littlejohns; Julie Makarski; Louise Zitzelsberger Journal: CMAJ Date: 2010-07-05 Impact factor: 8.262
Authors: Robert B Penfold; Christine Stewart; Enid M Hunkeler; Jeanne M Madden; Janet R Cummings; Ashli A Owen-Smith; Rebecca C Rossom; Christine Y Lu; Frances L Lynch; Beth E Waitzfelder; Karen J Coleman; Karen A Coleman; Brian K Ahmedani; Arne L Beck; John E Zeber; Gregory E Simon Journal: Curr Psychiatry Rep Date: 2013-12 Impact factor: 5.285
Authors: Justin Davis; Harris Eyre; Felice N Jacka; Seetal Dodd; Olivia Dean; Sarah McEwen; Monojit Debnath; John McGrath; Michael Maes; Paul Amminger; Patrick D McGorry; Christos Pantelis; Michael Berk Journal: Neurosci Biobehav Rev Date: 2016-04-09 Impact factor: 8.989
Authors: Andreas Reichert; Susanne Kreiker; Claudia Mehler-Wex; Andreas Warnke Journal: Child Adolesc Psychiatry Ment Health Date: 2008-02-27 Impact factor: 3.033
Authors: G Fond; O Godin; L Boyer; F Berna; M Andrianarisoa; N Coulon; L Brunel; E Bulzacka; B Aouizerate; D Capdevielle; I Chereau; T D'Amato; C Dubertret; J Dubreucq; C Faget; S Leignier; C Lançon; J Mallet; D Misdrahi; C Passerieux; R Rey; A Schandrin; M Urbach; P Vidailhet; P M Llorca; F Schürhoff; M Leboyer Journal: Eur Arch Psychiatry Clin Neurosci Date: 2018-05-28 Impact factor: 5.270
Authors: C U Correll; Ofer Agid; Benedicto Crespo-Facorro; Andrea de Bartolomeis; Andrea Fagiolini; Niko Seppälä; Oliver D Howes Journal: CNS Drugs Date: 2022-06-27 Impact factor: 6.497